# VIKING THERAPEUTICS, INC. (VKTX) · Edgar & Edgarette company card

> Viking Therapeutics (VKTX) reported revenue of $0 million in FY2025, operating margin null against a -3.8% median for pharmaceutical preparations, equity 89.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1607678 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VKTX) · [JSON](https://www.pops4.com/boards/company/VKTX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$279M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $166M |
| Long-term debt | — |
| Total assets | $716M |
| Total equity | $639M |
| Equity ÷ assets | 89.3% |
| Return on equity | -56.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 7.05 (safe zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$278.7M in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: one year on record; operating margin null, up from null. Soundness: equity 89.3% of assets, return on equity -56.3%. Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/0001193125-26-436432-index.htm)
- 8-K · filed 2026-10-28 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436145/0001193125-26-436145-index.htm)
- 8-K · filed 2026-09-28 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1607678/000119312526405580/0001193125-26-405580-index.htm)
- 8-K · filed 2026-09-22 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/0001193125-26-397219-index.htm)
- 10-Q · filed 2026-07-29 · [filing](https://www.sec.gov/Archives/edgar/data/1607678/000119312526324219/0001193125-26-324219-index.htm)
- 8-K · filed 2026-07-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/0001193125-26-323652-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001607678.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1607678

## Cite

POPS4, Edgar & Edgarette: VIKING THERAPEUTICS, INC. (VKTX) company card, from the company's own SEC filings, accessed 2026-11-12, https://www.pops4.com/boards/company/VKTX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.